BMJ  2003;326:1073-1077 (17 May), doi:10.1136/bmj.326.7398.1073

Clinical review

Science, medicine, and the future

New pacing technologies for heart failure

Anthony W C Chow, consultant cardiologist1, Rebecca E Lane, research fellow2, Martin R Cowie, professor of cardiology3

1 Department of Cardiology, Royal Berkshire and Battle Hospital, Reading RG30 1AJ, 2 Department of Cardiology, St Mary's Hospital, London W2 1NY, 3 Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London SW3 6LY

Correspondence to: A W C Chow anthony.chow@rbbh-tr.nhs.uk

Heart failure is a sizeable problem in elderly populations, and although pharmacological treatment has improved, outcome generally remains poor. New pacing technologies have been developed to treat heart failure, with promising results

The first 150 words of the full text of this article appear below.

Introduction

The prevalence of heart failure in the general population is estimated to be 1-2% and increases rapidly with age.1 In developed countries heart failure is a leading cause of admission to hospital among elderly patients and accounts for 1-2% of healthcare expenditure.2 Although several pharmacological treatments have improved outcome,3–5 the prognosis of patients with heart failure remains poor. Alternative non-pharmacological approaches including cardiac transplantation have been limited by availability of organs, and the use of artificial left ventricular assist devices remains restricted.

Recently, several promising new developments have taken place in pacing technology to treat selected patients with heart failure. These include atrio-biventricular pacing to correct abnormal patterns of left ventricular contraction and implantable cardiac defibrillators for treatment of malignant ventricular arrhythmias. As the scale of the problem becomes apparent new treatments that have been shown to improve morbidity and possibly mortality in patients with chronic heart failure will undoubtedly . . . [Full text of this article]

Methods

Conclusion


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials
Simon K H Lam and Andrew Owen
BMJ 2007 335: 925. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Lam, S. K H, Owen, A. (2007). Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 335: 925-925 [Abstract] [Full text]  
  • Ellery, S, Williams, L, Frenneaux, M (2006). Role of resynchronisation therapy and implantable cardioverter defibrillators in heart failure. Postgrad. Med. J. 82: 16-23 [Abstract] [Full text]  
  • Magner, J. J., Royston, D. (2004). Heart failure. Br J Anaesth 93: 74-85 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Limitation of benefit of CRT in severe heart failure (Class IV)
Munir Emile Nassar, M.D.
bmj.com, 30 May 2003 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ